Intel brings 3nm production to Europe in 2025
By Nick Flaherty, eeNews Europe (March 28, 2025)
Intel is shifting high volume production of 3nm chips to Europe at its Fab34 in Ireland later this year.
Intel 3 is the company’s second EUV lithography node with an 18% performance-per-watt improvement over Intel 4. The process is offered to foundry customers and was in high-volume manufacturing in Oregon during 2024, with high-volume manufacturing shifted to Leixlip in Ireland for 2025, it said in its annual report. This is the first confirmation of 3nm production after ramping up the first generation EUV process.
The Xeon 6 Scalable server processor offerings are built on this technology.
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |
Related News
- Analog Bits to Demonstrate IP Portfolio on TSMC 3nm and 2nm Processes at TSMC 2025 Technology Symposium
- Latest intoPIX JPEG XS Codec Powers FOR-A's FA-1616 for Efficient IP Production at NAB 2025
- Logic Fruit Technologies to Showcase Innovations at Embedded World Europe 2025
- Analog Bits to Join Intel Foundry Services Chip Design Ecosystem Expanding 3nm IP Offerings
- MediaTek Successfully Develops First Chip Using TSMC's 3nm Process, Set for Volume Production in 2024
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- SiFive and Kinara Partner to Offer Bare Metal Access to RISC-V Vector Processors
- Imagination Announces E-Series: A New Era of On-Device AI and Graphics
- Siemens to accelerate customer time to market with advanced silicon IP through new Alphawave Semi partnership
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design